- Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 results ($M): Total Revenues: 413.8 (+33.6%); Product Revenues: 409.7 (+35.4%).
- Net Income: (41.8) (+56.0%); Non-GAAP Net Income: 40.1 (+225.7%); EPS: (0.17) (+56.4%); Non-GAAP EPS: 0.16 (+223.1%).
- Key Product Sales: ORKAMBI: 234.0 (+78.6%); KALYDECO: 175.6 (+5.8%).
- 2016 Guidance: ORKAMBI Sales: $950M - 990M (unchanged from September update but lower than previous outlook of $1.0B - 1.1B); KALYDECO Sales: $685M - 705M (unch).
Vertex Pharmaceuticals Q3 revenues up 35%; net income up 56%; Orkambi sales up 79%
Recommended For You
About VRTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VRTX | - | - |
Vertex Pharmaceuticals Incorporated |